Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Rowan University Tackles Challenges of Reducing Carbon Footprint of Drug Manufacturing

22.07.2010
Rowan University faculty and students have teamed with Pfizer Global Engineering and Manufacturing personnel to investigate green approaches to drug manufacture. This is the second time Rowan has partnered with Pfizer to investigate methods to reduce the carbon footprint of pharmaceutical plant operations.

This year, the Rowan team has worked with scientists and engineers from Peapack, N.J., and the Kalamazoo, Mich., plant where drugs such as the widely prescribed SOLU-MEDROL® are made along with other highly specialized medicines.

The Rowan team has been working with several Pfizer personnel, including Frank J. Urbanski (director, Pfizer Global Engineering), Joseph W. Geiger (manager API engineering), and Donald J. Knoechel (senior principal scientist).

The team has collaborated to analyze the economic viability and to quantify the environmental benefits of investing in a small solvent recovery system, as an alternative to incineration, for addressing smaller-volume waste streams. Solvents often represent the primary component of waste from the production of active pharmaceutical ingredients (APIs), used in medicinal formulations.

According to Urbanski, “There are economic and environmental benefits when Pfizer recovers solvent for re-use, especially when expensive solvents and large volumes are involved. Indeed, Pfizer has been recovering solvents for many decades at its various manufacturing facilities. As we seek to improve our conservation efforts and reduce our carbon footprint, one challenge faced is how best to deal with numerous small-volume waste streams from multi-product facilities, when existing solvent recovery equipment may be too large to be practical.”

Solvent recovery is a routine practice in the pharmaceutical industry when it is technically and economically viable for the particular waste stream. Capital investment in the required piping, tank farms and recovery equipment is more easily justified when dealing with large volumes, high-cost solvents and high equipment-utilization rates and when solvents from multiple products can be pooled together – i.e., they don’t require segregation by product. The use of recovered solvents, and the pooling of solvents, must be appropriately qualified to assure product quality and avoid cross contamination. Economic justification to recover small-volume, “non-poolable,” and intermittently generated waste streams remains challenging but a potential recovery opportunity.

Drs. Mariano J. Savelski and C. Stewart Slater, both Rowan chemical engineering professors, are leading this research effort with a team of chemical engineering students: Joseph Hankins (Blairstown, N.J.), Christopher Mazurek (Jackson, N.J.), James Peterson (Jackson, N.J.), Michael Raymond (Burlington Township, N.J.), and Andrew Tomaino (Middleton, N.J.).

The Rowan team performed a case study on several waste streams being generated at an API synthesis building at the Pfizer Kalamazoo plant. The goal was to investigate those streams that could be most easily recovered with traditional separation and purification processes. As a first step in that analysis, the recovery of acetonitrile solvent from a waste stream in the selamectin synthesis was considered. Selamectin is the active ingredient in the veterinary drug REVOLUTION®. This stream was initially chosen due to the relative high cost (and value) of acetonitrile and the ability to separate acetonitrile from acetone.

Rowan designed a small-scale distillation, solvent-recovery system, and the proposed operation compared with the current waste-disposal practice. To increase the economic feasibility of a potential capital investment and improve the environmental footprint further, the Rowan team evaluated the proposed design for use with the other waste streams in the facility. The simulation included isopropanol solvent recovery from the manufacture of nelfinavir, the active ingredient in the antiretroviral drug VIRACEPT®, used in the treatment of the human immunodeficiency virus (HIV). The study also examined toluene recovery from hydrocortisone manufacture (used in several drug products for relief of inflammation).

“The case study estimates the environmental impacts and economics, using life-cycle assessment, associated with the proposed improvement using various computer routines,” Savelski said.

Knoechel said, “From a plant perspective, the Rowan team has given us some valuable estimates to use in evaluating our solvent use and disposal practices. The team’s unique life-cycle assessment capability helps us understand where we can have the most impact on reducing our greenhouse gas emissions.”

The case study for the three drugs showed that 732,000 kg/yr of life cycle emissions, of which 677,000 kg/yr are CO2, could be reduced through using the solvent recovery system. This results from not having to manufacture the virgin solvent as well as from a reduction in waste disposal. The study also projects significant operating cost benefit. The CO2 reductions are equivalent to the amount of emissions saved by not driving cars 1.4 million miles in a year.

The Rowan group presented its work at the 14th Green Chemistry and Engineering Conference in Washington, D.C., in June.

Both Pfizer and Rowan recently have been recognized for their green chemistry and engineering achievements. Pfizer’s La Jolla (Calif.) research and development facility won a Clean Air Champions award from the County of San Diego in 2009. Rowan’s Savelski and Slater won the EPA’s Environmental Quality Award in 2009 for their efforts in educating both academia and industry in the field of green engineering. Rowan University’s prior work with Pfizer resulted in recommendations to improve the solvent-recovery operations in the manufacture of celecoxib, the active ingredient in the arthritis pain medication CELEBREX®.

Pfizer and Rowan continue to discuss further green engineering partnerships.

*Celebrex®, Revolution®, Solu-Medrol® and Viracept® are registered trademarks of Pfizer Inc. and its affiliated companies

Patricia Quigley | Newswise Science News
Further information:
http://www.rowan.edu

More articles from Life Sciences:

nachricht A novel synthetic antibody enables conditional “protein knockdown” in vertebrates
20.08.2018 | Technische Universität Dresden

nachricht Climate Impact Research in Hannover: Small Plants against Large Waves
17.08.2018 | Leibniz Universität Hannover

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: It’s All in the Mix: Jülich Researchers are Developing Fast-Charging Solid-State Batteries

There are currently great hopes for solid-state batteries. They contain no liquid parts that could leak or catch fire. For this reason, they do not require cooling and are considered to be much safer, more reliable, and longer lasting than traditional lithium-ion batteries. Jülich scientists have now introduced a new concept that allows currents up to ten times greater during charging and discharging than previously described in the literature. The improvement was achieved by a “clever” choice of materials with a focus on consistently good compatibility. All components were made from phosphate compounds, which are well matched both chemically and mechanically.

The low current is considered one of the biggest hurdles in the development of solid-state batteries. It is the reason why the batteries take a relatively long...

Im Focus: Color effects from transparent 3D-printed nanostructures

New design tool automatically creates nanostructure 3D-print templates for user-given colors
Scientists present work at prestigious SIGGRAPH conference

Most of the objects we see are colored by pigments, but using pigments has disadvantages: such colors can fade, industrial pigments are often toxic, and...

Im Focus: Unraveling the nature of 'whistlers' from space in the lab

A new study sheds light on how ultralow frequency radio waves and plasmas interact

Scientists at the University of California, Los Angeles present new research on a curious cosmic phenomenon known as "whistlers" -- very low frequency packets...

Im Focus: New interactive machine learning tool makes car designs more aerodynamic

Scientists develop first tool to use machine learning methods to compute flow around interactively designable 3D objects. Tool will be presented at this year’s prestigious SIGGRAPH conference.

When engineers or designers want to test the aerodynamic properties of the newly designed shape of a car, airplane, or other object, they would normally model...

Im Focus: Robots as 'pump attendants': TU Graz develops robot-controlled rapid charging system for e-vehicles

Researchers from TU Graz and their industry partners have unveiled a world first: the prototype of a robot-controlled, high-speed combined charging system (CCS) for electric vehicles that enables series charging of cars in various parking positions.

Global demand for electric vehicles is forecast to rise sharply: by 2025, the number of new vehicle registrations is expected to reach 25 million per year....

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

LaserForum 2018 deals with 3D production of components

17.08.2018 | Event News

Within reach of the Universe

08.08.2018 | Event News

A journey through the history of microscopy – new exhibition opens at the MDC

27.07.2018 | Event News

 
Latest News

Metamolds: Molding a mold

20.08.2018 | Information Technology

It’s All in the Mix: Jülich Researchers are Developing Fast-Charging Solid-State Batteries

20.08.2018 | Power and Electrical Engineering

Smallest transistor worldwide switches current with a single atom in solid electrolyte

17.08.2018 | Physics and Astronomy

VideoLinks
Science & Research
Overview of more VideoLinks >>>